MA53493A - Polypeptides leurres - Google Patents

Polypeptides leurres

Info

Publication number
MA53493A
MA53493A MA053493A MA53493A MA53493A MA 53493 A MA53493 A MA 53493A MA 053493 A MA053493 A MA 053493A MA 53493 A MA53493 A MA 53493A MA 53493 A MA53493 A MA 53493A
Authority
MA
Morocco
Prior art keywords
lures
polypeptides
polypeptides lures
Prior art date
Application number
MA053493A
Other languages
English (en)
French (fr)
Inventor
Jaume Pons
Bang Janet Sim
Original Assignee
Alx Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alx Oncology Inc filed Critical Alx Oncology Inc
Publication of MA53493A publication Critical patent/MA53493A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA053493A 2018-08-31 2019-08-29 Polypeptides leurres MA53493A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862725977P 2018-08-31 2018-08-31

Publications (1)

Publication Number Publication Date
MA53493A true MA53493A (fr) 2021-07-07

Family

ID=67997686

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053493A MA53493A (fr) 2018-08-31 2019-08-29 Polypeptides leurres

Country Status (5)

Country Link
US (1) US20210347848A1 (enExample)
EP (1) EP3843772A2 (enExample)
JP (1) JP2021534769A (enExample)
MA (1) MA53493A (enExample)
WO (1) WO2020047326A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
WO2021108693A1 (en) 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
JP2023528341A (ja) * 2020-06-01 2023-07-04 エーエルエックス オンコロジー インコーポレイテッド 低メチル化剤を含むがんを治療するための併用療法
WO2022120286A1 (en) * 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
WO2025222106A1 (en) * 2024-04-18 2025-10-23 Aktis Oncology, Inc. Decoy miniproteins, compositions, & methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US20030118997A1 (en) * 2001-08-10 2003-06-26 Genset, S.A. Human cDNAs and proteins and uses thereof
US7074891B2 (en) * 2003-02-07 2006-07-11 Posco Leukocyte stimulating peptides
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0923442A2 (pt) * 2008-12-19 2016-01-12 Novartis Ag polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios.
DK2429574T3 (da) * 2009-05-15 2015-06-22 Univ Health Network Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
BR112013027224A8 (pt) * 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
ME03550B (me) * 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
WO2016023040A1 (en) * 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
DK3298043T3 (da) * 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
RU2740672C2 (ru) * 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
EA034582B1 (ru) * 2015-08-07 2020-02-21 АЭлЭкс ОНКОЛОДЖИ ИНК. Конструкции варианта sirp-альфа и их применение
WO2018118887A1 (en) * 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
EP3936526A4 (en) * 2019-03-06 2023-03-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF

Also Published As

Publication number Publication date
WO2020047326A2 (en) 2020-03-05
US20210347848A1 (en) 2021-11-11
WO2020047326A3 (en) 2020-04-09
JP2021534769A (ja) 2021-12-16
EP3843772A2 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
EP3801265B1 (en) URINARY FLOWMETER
FIC20253006I1 (fi) Linvoseltamabi
EP3890716A4 (en) COMBINATION THERAPIES
LT3890488T (lt) Herbicidiniai deriniai
EP3846674C0 (en) VAGINAL SPECULUM
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
EP3802565A4 (en) POLYPEPTIDES
EP3872558A4 (en) OPTICAL ISOLATOR
DK3737402T5 (da) Modificeret protein
EP3904196A4 (en) SHIP
EP3878374A4 (en) OKKLUDER
EP3721129C0 (en) Cryosphere
EP3870698A4 (en) ANTIPATHOGENIC POLYPEPTIDES
EP3844177A4 (en) COMBINATION THERAPIES
DK3587968T3 (da) Fluidsystem
DK3752258T3 (da) Trampolin
EP3773733A4 (en) METALLO-LIOTHYRONINE
ES1207586Y (es) Furgo-caravana
EP3787995C0 (en) HARNESS SADDLE
MA49925A (fr) Claie
DE112019000442A5 (de) Ringtilgereinrichtung
NO20181678A1 (no) Rissanviser
ES1214389Y (es) Plomo de pesca anti-enroque
JP1628555S (ja) たい焼
JP1628556S (ja) たい焼